BHCM
ZNTL icon

Brevan Howard Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Brevan Howard Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Buy
+47,063
New +$122K ﹤0.01% 2002
2025
Q1 		– Sell
-26,351
Closed -$79.8K – 1525
2024
Q4 		$79.8K Buy
26,351
+10,903
+71% +$35.7K ﹤0.01% 978
2024
Q3 		$56.8K Sell
15,448
-5,791
-27% -$21K ﹤0.01% 1091
2024
Q2 		$86.9K Buy
21,239
+7,635
+56% +$85.3K ﹤0.01% 978
2024
Q1 		$214K Buy
+13,604
New +$187K ﹤0.01% 776

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Brevan Howard Capital Management's ZNTL Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 47,063 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #2002 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in ZNTL as recently as Q4 2024.

Brevan Howard Capital Management first reported a position in ZNTL in Q1 2024 and has held it in 5 quarters since. The position peaked at $214K in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Brevan Howard Capital Management held 47,063 shares of Zentalis Pharmaceuticals worth $110K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Brevan Howard Capital Management position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2002 holding.
  • Brevan Howard Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • Brevan Howard Capital Management's Zentalis Pharmaceuticals position peaked at $214K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.